共查询到10条相似文献,搜索用时 0 毫秒
1.
J Kanerva T Niini K Vettenranta P Riikonen A M?kipernaa R Karhu S Knuutila U M Saarinen-Pihkala 《Medical and pediatric oncology》2001,37(5):419-425
BACKGROUND: Genetic aberrations provide prognostic information in childhood ALL. The proportion of patients with detectable aberrations can be increased by combining G-banding with comparative genomic hybridization (CGH). PROCEDURE: We studied 79 children with ALL by CGH and G-banding, and explored the relationship of these findings to clinical features and outcome. RESULTS: CGH revealed DNA copy number changes in 57 patients (72%), 9 of whom had normal karyotype by G-banding. Gains were more frequent than losses, and changes of whole chromosomes more frequent than partial aberrations. Two frequent partial losses were found; at 9p and 12p. The 9 patients with loss at 12p were studied for the deletion of TEL (ETV6) gene and the fusion of TEL and AML1 genes by fluorescent in situ hybridization (FISH). Eight out of the 9 children with loss at 12p harbored the TEL-AML1 translocation and all 9 had the deletion of a nontranslocated TEL allele. All 9 had precursor-B phenotype and L1 morphology, and 8/9 had WBC below 50 x 10(9)/liter. All children were treated according to Nordic ALL protocols, had a good response to treatment based on day 15 bone marrow morphology, and 7 out of the 9 survived in continuous complete remission (median follow-up 74 months). CONCLUSIONS: CGH is a valuable tool in screening for genetic aberrations in childhood ALL. DNA copy number losses detected at 12p associate with TEL-AML1 fusion as well as with favorable prognostic features. 相似文献
2.
3.
4.
5.
6.
Nobuhiro Suzuki MD PhD Keiko Yumura‐Yagi MD PhD Makoto Yoshida MD PhD Junichi Hara MD PhD Shinichiro Nishimura MD PhD Tooru Kudoh MD PhD Akio Tawa MD PhD Ikuya Usami MD PhD Akihiko Tanizawa MD PhD Hiroki Hori MD PhD Yasuhiko Ito MD PhD Ryosuke Miyaji MD PhD Megumi Oda MD PhD Koji Kato MD PhD Kazuko Hamamoto MD PhD Yuko Osugi MD PhD Yoshiko Hashii MD PhD Tatsutoshi Nakahata MD PhD Keizo Horibe MD PhD 《Pediatric blood & cancer》2010,54(1):71-78
7.
8.
9.
Renáta László MD Donát Alpár PhD Béla Kajtár MD Ágnes Lacza MSc Gábor Ottóffy MD Csongor Kiss MD PhD DSc Katalin Bartyik MD Kálmán Nagy MD PhD CSc László Pajor MD PhD CSc 《Pediatric blood & cancer》2010,54(1):158-160
DNA‐, RNA‐, and cell‐based methods provide different biologic information for determining the presence of minimal residual disease (MRD). We monitored the responses of patients with pediatric acute lymphoblastic leukemia (pALL) using DNA markers, TEL/AML1 expression, and scanning fluorescence microscopy (SFM). Using SFM, 36% of patients exhibited 1.5–3.1 log and 2.9–4.2 log higher MRD levels compared with those based on DNA and RNA markers, respectively. CD10+ ancestor cells with germline antigen receptors, but silent TEL/AML1 expression, may reside in the lymphoid stem cell compartment of treated t(12;21)‐positive patients and might act as a potential source of cells for late relapses. Pediatr Blood Cancer 2010; 54:158–160. © 2009 Wiley‐Liss, Inc. 相似文献
10.